AGM
ADPT icon

Alpine Global Management’s Adaptive Biotechnologies ADPT Stock Holding History

Alpine Global Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,008
Closed -$122K – 140
2022
Q4 		$122K Buy
+16,008
New +$125K 0.04% 141
2022
Q1 		– Sell
-26,526
Closed -$744K – 437
2021
Q4 		$744K Buy
+26,526
New +$813K 0.11% 194

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Alpine Global Management's ADPT Position: Q1 2023 in Review

Alpine Global Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 16,008 shares — an estimated $122K sold.

Alpine Global Management first reported a position in ADPT in Q4 2021 and held it in 2 quarters. The position peaked at $744K in Q4 2021. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

  • Alpine Global Management reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 16,008 Adaptive Biotechnologies shares in Q1 2023, an estimated $122K.
  • Alpine Global Management first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 2 quarters.
  • Alpine Global Management's Adaptive Biotechnologies position peaked at $744K in Q4 2021.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.